A mathematical approach to estimate the efficacy of individual‐donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections

Abstract

The efficacy of the currently available commercial NAT systems in reducing HBV transmission risk is mainly driven by the pool size and the transfusion plasma volume. The modeled OBI transmission risk and NAT efficacy levels were in line with those recently reported in three lookback studies and give more insight in the incremental safety provided by HBsAg and antibody to hepatitis B core antigen testing of ID-NAT screened blood.